SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-042902
Filing Date
2024-10-29
Accepted
2024-10-29 16:30:23
Documents
16
Period of Report
2024-10-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 90055
2 ex10-1.htm EX-10.1 104561
3 ex10-2.htm EX-10.2 116896
4 ex10-3.htm EX-10.3 111570
  Complete submission text file 0001493152-24-042902.txt   675775

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE erna-20241029.xsd EX-101.SCH 3015
6 XBRL LABEL FILE erna-20241029_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE erna-20241029_pre.xml EX-101.PRE 24165
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3698
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 241406178
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)